Key clinical point: Updated results from the TRANSCEND NHL trial include survival data with lisocabtagene maraleucel, an anti-CD19 chimeric antigen receptor T-cell therapy, in patients with relapsed/refractory B-cell lymphomas.
Major finding: The median progression-free survival was 6.8 months, and the median overall survival was 21.1 months.
Study details: A phase 1 trial of 269 patients diagnosed with diffuse large B-cell lymphoma (not otherwise specified), transformed follicular lymphoma or other indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma.
Disclosures: The trial is sponsored by Bristol-Myers Squibb. Dr. Abramson reported relationships with Juno Therapeutics and Celgene, now owned by Bristol-Myers Squibb, and a range of other companies.
Abramson JS et al. ASH 2019, Abstract 241.